BioAge Labs, Inc.
NMS: BIOALive Quote
📈 ZcoreAI Score
Our AI model analyzes BioAge Labs, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get BIOA Z-Score →About BioAge Labs, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
📊 Fundamental Analysis
BioAge Labs, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -27.1%, which indicates that capital utilization is currently under pressure.
At a current price of $16.19, BIOA currently sits at the 62nd percentile of its 52-week range (Range: $3.62 - $24.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$718.51M
Trailing P/E
--
Forward P/E
-5.83
Beta (5Y)
--
52W High
$24.00
52W Low
$3.62
Avg Volume
644K
Day High
Day Low